Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine and L-DOPA in Severe TBI Patients with DOC
NCT04244058Phase 1Suspended
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of levodopa in disorder of consciousness (DOC) and traumatic brain injury (TBI), sponsored by Weill Cornell Medicine. Primary endpoint: Delta changes in binding potential nondisplaceable at Day 2. Started Sep 2020; status: suspended.
02
Drugs
levodopa
03
Conditions
disorder of consciousness (DOC)traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT04244058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244058.